Results 51 to 60 of about 1,993 (117)

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience

Endocrine Oncology
Objective: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE is increasingly used in the treatment of metastatic neuroendocrine neoplasms (NENs). Marrow toxicity resulting in therapy-related myeloid neoplasms (t-MNs) remains a rare but
Wallace Chow, Ivy Wen, Claire Mok, Kathryn Huang, William Stevenson, Paul J Roach, Dale L Bailey, Connie I Diakos, Stephen J Clarke, Nick Pavlakis, David L Chan   +10 more
doaj   +1 more source

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

Frontiers in Oncology, 2021
IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely.
Marta Opalińska, Anna Sowa-Staszczak, Anna Grochowska, Helena Olearska, Alicja Hubalewska-Dydejczyk   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

, 2023
Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing ...
Elettra Merola, Chiara Maria Grana, Merola E, Grana CM   +3 more
core   +1 more source

Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center

Indian Journal of Endocrinology and Metabolism
Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT).
David Mathew, Saumya S. Sunny, Justin Benjamin, Junita R. John, Felix K. Jebasingh, Josh T. Georgy, Ashish Singh, Regi Oommen   +7 more
doaj   +1 more source

Translating Asian‐Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021–2025

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT An increasing number of novel molecular entities and biosimilars reach the European Medicines Agency (EMA) supported by pivotal evidence derived predominantly from Asian patient populations. This creates regulatory challenges that the existing ICH E5 framework was not originally designed to address.
Prerona Boruah, Alex Zwiers
wiley   +1 more source

Can acromegaly be controlled in all cases?

Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Acromegaly is a rare disease, due in most of the cases to a growth hormone (GH)‐secreting pituitary adenoma (PA), namely neuroendocrine tumour (PitNET). The treatment of patients with acromegaly is multimodal and multi‐step, including surgery, medical therapies, and radiotherapy.
Sabrina Chiloiro, Francesco Padovano Sorrentino, Alessandra Vicari, Antonella Giampietro, Pier Paolo Mattogno, Quintino Giorgio D'Alessandris, Rosalinda Calandrelli, Tommaso Tartaglione, Marco Gessi, Simona Gaudino, Laura De Marinis, Guido Rindi, Francesco Doglietto, Antonio Bianchi, Alfredo Pontecorvi   +14 more
wiley   +1 more source

Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE

Endocrine Oncology
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity.
Eleonora Pelle, Taymeyah Al-Toubah, Ghassan El-Haddad, Brian Morse, Bhavana Konda, Vineeth Sukrithan, Jonathan Strosberg   +6 more
doaj   +1 more source

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BMC Cancer, 2019
Background NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET.
S. Rudisile, A. Gosewisch, V. Wenter, M. Unterrainer, G. Böning, F. J. Gildehaus, W. P. Fendler, C. J. Auernhammer, C. Spitzweg, P. Bartenstein, A. Todica, H. Ilhan   +11 more
doaj   +1 more source

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

, 2020
Purpose: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion.
Bodei L., Singh A., Malczewska A., Severi S., Krenning E. P., Baum R. P., Kwekkeboom D. J., Paganelli G., van der Zwan W. A., Modlin I. M., Kidd M. S., Drozdov I. A.   +11 more
core   +1 more source